Pre-market hot trades in US stocks: Lisata Therapeutics pre-market down 13.24%; Applied Materials pre-market up 3.67%
I'm LongbridgeAI, I can summarize articles.Lisata Therapeutics pre-market down 13.24%; Applied Materials pre-market up 3.67%; NextCure pre-market up 69.50%; Vision Marine Tech pre-market up 52.48%; Picard Medical pre-market up 50.81%
Pre-market Hot Trades in US Stocks
Lisata Therapeutics, down 13.24% in pre-market trading, has no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Applied Materials is up 3.67% in pre-market trading. Based on recent key news:
-
On July 13, Goldman Sachs released a research report maintaining a "Buy" rating on Applied Materials and raised the target price to $645. Goldman Sachs is optimistic about the long-term growth potential of DRAM and HBM, believing that the company's order visibility extends to 2028, driving the stock price up.
-
On July 13, TD Cowen and Mizuho Securities raised the target price for Applied Materials to $700 and $650, respectively. Analysts are optimistic about the investment boom driven by artificial intelligence, boosting the stock price.
-
On July 13, the market has optimistic expectations for Applied Materials' third-quarter performance, forecasting earnings per share of $3.39 and revenue of $8.94 billion, enhancing investor confidence. The semiconductor industry has significant growth potential, and export control risks need to be monitored.
Top Gainers in Pre-market US Stocks
NextCure is up 69.50% in pre-market trading. Based on recent news:
-
On July 14, NextCure Inc. released new research results showing significant progress of its new drug in clinical trials. This news greatly boosted market confidence, driving the stock price sharply higher.
-
On July 14, Hansoh Pharmaceutical Group Co. Ltd. announced a strategic cooperation agreement with NextCure on the Hong Kong Stock Exchange. This agreement will further enhance NextCure's R&D capabilities, and the market reacted positively, causing the stock price to rise.
-
On July 14, NextCure's latest financial report showed that the company's revenue and profit in the second quarter exceeded market expectations. This positive news further propelled the stock price upward. The biopharmaceutical industry has performed strongly recently, and investor sentiment is high.
Vision Marine Tech is up 52.48% in pre-market trading. Based on recent key news:
-
On July 13, Vision Marine Technologies released an important announcement through the EDGAR system, significantly driving up the stock price. The announcement involved the successful development and commercialization of the company's technology, enhancing market confidence and leading to a 52.48% pre-market increase in stock price. Source: EDGAR
-
On July 9, HRT Financial sold its remaining shares of Vision Marine Technologies. Although this move typically has a negative impact on stock prices, the market's optimistic sentiment about the company's future development offset this effect. Source: EDGAR
-
Recently, the company has made progress in battery supplier qualification certification and supply chain management, further consolidating its market position. Such positive business developments provide support for the stock price. Source: EDGAR Battery supply chain improvement, market confidence enhancement.
Picard Medical pre-market rose by 50.81%. There has been no significant news recently; trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news